1. Signaling Pathways
  2. Anti-infection
  3. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155734
    SARS-CoV-2-IN-55
    SARS-CoV-2-IN-55(compound 65) is a low cytotoxicity inhibtor of SARS-CoV-2 with an IC50 value of 0.3 μM, by the direct interaction with VSV-S pseudoparticles.
    SARS-CoV-2-IN-55
  • HY-155015
    SARS-CoV-2-IN-45
    Inhibitor
    SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect.
    SARS-CoV-2-IN-45
  • HY-146987
    FWM-3
    Inhibitor
    FWM-3 is a potent SARS-CoV-2 NSP13 helicase inhibitor.
    FWM-3
  • HY-124439
    Setomimycin
    Inhibitor
    Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity.
    Setomimycin
  • HY-163706
    SARS-CoV-2-IN-88
    Inhibitor
    SARS-CoV-2-IN-88 (compound 3a) is a potent SARS-CoV-2 inhibitor with inhibitory value of 96.00%.
    SARS-CoV-2-IN-88
  • HY-P99929
    Enuzovimab
    Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity.
    Enuzovimab
  • HY-N10604
    Dihydromaniwamycin E
    Inhibitor
    Dihydromaniwamycin E is a heat-shock metabolite with antiviral activity against influenza and SARS-CoV-2 viruses.
    Dihydromaniwamycin E
  • HY-168152
    SARS-CoV-2 3CLpro-IN-26
    Inhibitor
    SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells.
    SARS-CoV-2 3CLpro-IN-26
  • HY-147804
    SARS-CoV-2 3CLpro-IN-3
    Inhibitor
    SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities.
    SARS-CoV-2 3CLpro-IN-3
  • HY-P990705
    Gorivitug
    Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Gorivitug
  • HY-90001S2
    Ritonavir-d8
    Inhibitor
    Ritonavir-d8 is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.
    Ritonavir-d<sub>8</sub>
  • HY-152220
    SPR39
    Inhibitor
    SPR39 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.252, 3.38, 7.88 µM for SARS-CoV-2 Mpro, hCatL, hCatB, respectively. SPR39 shows antiviral and cytotoxicity.
    SPR39
  • HY-161790
    Mpro ligand 1
    Mpro ligand 1 is the ligand for target protein for PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789). Mpro ligand 1 is the active form of Mpro ligand 2 (HY-161791).
    Mpro ligand 1
  • HY-152009
    SARS-CoV-2 3CLpro-IN-7
    Inhibitor
    SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM.
    SARS-CoV-2 3CLpro-IN-7
  • HY-156325
    SARS-CoV-2-IN-62
    Inhibitor
    SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively.
    SARS-CoV-2-IN-62
  • HY-175029
    ALG-097558
    Inhibitor
    ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].
    ALG-097558
  • HY-133832
    Elopiprazole
    Inhibitor
    Elopiprazole can be used in study of neurological disease and SARS-CoV-2.
    Elopiprazole
  • HY-168430
    SARS-CoV-2 3CLpro-IN-30
    Inhibitor
    SARS-CoV-2 3CLpro-IN-30 (compound 29) is a potent inhibitor of SARS-CoV-2 3CL protease (SARS-CoV-2 3CLpro), with the IC50 and EC50 of 0.04 and 0.3 μM.
    SARS-CoV-2 3CLpro-IN-30
  • HY-151990
    SARS-CoV-2/MERS Mpro-IN-1
    Inhibitor
    SARS-CoV-2/MERS Mpro-IN-1 (compound 9c) is a potent SARS-CoV-2 and MERS main protease inhibitor with IC50 values of 0.10, 0.06 µM, respectively.
    SARS-CoV-2/MERS Mpro-IN-1
  • HY-162484
    GZNL-P36
    Inhibitor
    GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse.
    GZNL-P36
Cat. No. Product Name / Synonyms Species Source